SYSTEMIC MASTOCYTOSIS: CLINICAL AND MORPHOLOGICAL ANALYSIS FIVE PATIENTS WITH A RARE DISEASE



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The central component of the diagnosis of systemic mastocytosis is a morphological study of the affected organ, which is aimed at assessing the volume of tumor infiltration and the pattern of damage, which may reflect the biological properties of the tumor and the prognosis of the disease. The material for the study was trephination biopsies and bone marrow smears of 5 patients with systemic mastocytosis, aged 17 to 68 years. Paraffin sections were stained with hematoxylin and eosin, azure by Romanovsky, and immunohistochemistry was performed with antibodies to CD25 (Interleukin-2 receptor alpha chain), CD2 (T-cell surface antigen T11/Leu-5), CD117 (Mast/ stem cell growth factor receptor) and tryptase. Bone marrow smears stained by Romanovsky-Giemsa. At the time of the diagnosis, the 2016 WHO revision classification was used. In all patients, a tumor was detected in SM. In the indolent form, the bone marrow diseases were located singly and discretely, and they also formed perisinusoidal and perivascular clusters up to 10-15 cells, the total number of which did not exceed 15% of all nucleated cells. On the contrary, in case of smouldering form (n=2), a nodular lesion pattern was revealed, in which mas-tocytes formed para- and intertrabecular foci of various shapes with sizes up to 200-300 cells, with a total volume of tumor infiltration of 36 and 43%. In two patients with an aggressive form of the disease, the infiltration volume of CM was 65 and 75%, while in both cases diffuse growth was observed, with a subtotal substitution of most of the bone marrow lacunae, with narrowing of hemopoiesis, as well as the appearance of secondary dysplasia features in erythroid and megakaryocytic lineages. Thus, the clinical manifestations of the disease correlate with the volume and pattern of CM damage in SM.

Full Text

Restricted Access

About the authors

I. L Plaksa

Moscow City Oncology Hospital № 62; PJSC «Human Stem Cells Institute»

Email: i.plaksa2014@yandex.ru

S. S Savin

I.P. Pavlov the First Saint-Petersburg State Medical University

E. M Charlanova

I.P. Pavlov the First Saint-Petersburg State Medical University

V. M Kravcova

I.P. Pavlov the First Saint-Petersburg State Medical University

B. V Afanasiev

I.P. Pavlov the First Saint-Petersburg State Medical University

References

  1. Valent P., Akin C., Metcalfe D. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017; 129: 1420-7.
  2. Patnaik M.M., Rindos M., Kouides P.A. et al. Systemic mastocytosis: a concise clinical and laboratory review. Arch. Pathol. Lab. Med. 2007; 131: 784-91.
  3. Захарцева Л.М., Шатрова К.М., Крячок И.А. и др. Системный мастоцитоз с преимущественным поражением костной и лимфатической системы (обзор литературы и случай из практики). Онкология 2015; 17(4): 236-43.
  4. Butterfield J.H., Li C.Y. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? Am. J. Clin. Pathol. 2004; 121(2): 264-7.
  5. Reichard K.K., Chen D., Pardanani A. et al. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Am. J. Clin. Pathol. 2015; 144(3): 493-502.
  6. Sotlar K., Horny H.P., Simonitsh I. et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis in routinely processed bone marrow biopsy specimens. Am. J. Surg. Pathol. 2004; 28: 1319-25.
  7. Cherian S., McCullouch V., Miller V. et al. Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis. Cytometry B. Clin. Cytom. 2016; 90(4): 387-92.
  8. Teodosio C., Garcia-Montero A.C., Jara-Acevedo M. et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J. Allergy Clin. Immunol. 2010; 125(3): 719-26.
  9. Morgado J.M., Sanchez-Munoz L., Teodosio C.G. et al. Immunophenotyping in systemic mastocytosis diagnosis: CD25 positive alone is more informative than the CD25 and/or CD2 WHO criterion. Mod. Pathol. 2012; 25(4): 516-21.
  10. Escribano L., Alvarez-Twose I., Sanchez-Munoz L. et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J. Allergy Clin. Immunol. 2009; 124(3): 514-21.
  11. Barete S., Assous N., Grandpeix C. et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann. Rheum. Dis. 2010; 69(10): 1838-41.
  12. Bonifacio M., Zanotti R., Guardalben E. et al. Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis. Clin. Case Rep. 2017; 5(12): 1988-91.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies